期刊文献+

伊马替尼治疗不可切除胃间质瘤部分缓解一例并文献复习 被引量:3

原文传递
导出
摘要 目的评估甲磺酸伊马替尼对胃肠间质瘤(GIST)的疗效和安全性,探讨不可切除GIST的治疗方案。方法结合我院1例GIST患者,通过检索Pub Med、万方、中国知网(CNKI)等数据库,查阅有关长期大样本临床试验及不可切除GIST治疗的文献,对伊马替尼治疗不可切除GIST的疗效及安全性进行评价。结果本例患者59岁,女性,剖腹探查发现肿瘤源于胃大弯侧,与周围组织大部分浸润性粘连,仅行活检术。病理提示:胃间质瘤,核分裂象>5/50 HPF。免疫组化:CD117(+),DOG1(-)。口服伊马替尼400 mg/d,定期复查CT,肿瘤明显缩小,期间出现过轻微的恶心、腹泻、水肿及白细胞减少,予对症处理后恢复正常。查阅发现两项国外长达10年的多中心试验,表明长期使用伊马替尼治疗不可切除GIST有较好的疗效及较小的毒副作用。结论如同两项国外研究结果,伊马替尼治疗本例患者效果明显,副作用小。此时联合手术是否更有益于患者,尚需长期大样本多中心对照试验证实。
出处 《中华临床医师杂志(电子版)》 CAS 2015年第7期143-146,共4页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献18

  • 1Corlcss CL, Fletcher JA, Heinrich MC. Biology of Gastrointestinal Stromal Tumors[J]. J Clin Oncol, 2004, 22(18): 3813-3825.
  • 2Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal turnouts: origin and molecular oneology[J]. Nat Rev Cancer, 2011, 11(12): 865-878.
  • 3Hamberg P, de Jong FA, Boonstra JG, et al. Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib[J]. J Clin Oncol, 2006, 24(18): 30-31.
  • 4Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumors[J]. Lancet Oneol, 2002, 3(11): 655-664.
  • 5Peng B, Lloyd P, Schran H. Clinical pharmacokinctics of imatinib[J]. Clin Pharmacokinet, 2005, 44(9): 879-894.
  • 6DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival[J]. Ann Surg, 2000, 231(1): 51-58.
  • 7Blanke CD, Demetri GD, von Mehren M, et al. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT[J]. J Clin Oncol, 2008, 26(4): 620-625.
  • 8Patel S. Long-term efficacy of imatinib for tzeatment of metastatic GIST[J]. Cancer Chemother Pharmacol, 2013, 72(2): 277-286.
  • 9Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002, 347(7): 472-480.
  • 10Blanke CD, Rankin C, Dcmetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesykate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033[J]. J Clin Oncol, 2008, 26(4): 626-632.

二级参考文献7

共引文献231

同被引文献39

  • 1郑媛媛.肿瘤的单抗靶向疗法在国内的研究和应用进展[J].中国肿瘤生物治疗杂志,2006,13(1):70-72. 被引量:2
  • 2Matta A,Ralhan R.Overview of current and future biologically based targeted therapies inhead and neck squamous cell carcinoma[J].Head Neck Oncol,2009,1:6.
  • 3Simader C,Ritter M,Bolz M,et al.Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration[J].Ophthalmology,2014,121(6):1237-1245.
  • 4Mittendorf EA,Alatrash G,Xiao H,et al.Breast cancer vaccines:ongoing National Cancer Institute-registered clinical trials[J].Expert Rev Vaccines,2011,10(6):755-774.
  • 5Lynch TJ Jr,Kim ES,Eaby B,et al.Epidermal growth factor receptor inhibitor-associated cutaneous toxicities:anevolving paradigm in clinical management[J].Oncologist,2007,12(5):610-621.
  • 6Hirsh V.Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lunge cancer[J].Current Oncology,2011,18(3):126-138.
  • 7Lacouture M,Melosky B.Cutaneous reactions to anticancer agents targeting the epidermal growth material protected by copright factor receptor:A dermatology-oncology perspective[J].Skin Therapy Letter,2007,12:1-5.
  • 8Reyes-Habito CM,Roh EK.Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer:Part.Targeted herapy[J].J Am Acad Dermatol,2014,71(2):217.
  • 9Carlmark A,Hawker C,Hult A,et al.New methodologies in the construction of dendritic materials[J].Chem Soc Rev,2009,38(2):352-362.
  • 10Melosky B,Burkes R,Rayson D.Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal maligancies:Canadian recommendations[J].Current Oncology,2009,16(1):16-26.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部